Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment
Harrys A. Torres(The University of Texas MD Anderson Cancer Center), Ahmed O. Kaseb(The University of Texas MD Anderson Cancer Center), Parag Mahale(National Cancer Institute), Jean‐Nicolas Vauthey(The University of Texas MD Anderson Cancer Center), Minas P. Economides(NYU Langone Health)
Cited by 79
Related Papers
Posthepatectomy liver failure: A definition and grading by the International Study Group of Liver Surgery (ISGLS)
|Surgery|2011|2.3k
Bile leakage after hepatobiliary and pancreatic surgery: A definition and grading of severity by the International Study Group of Liver Surgery
|Surgery|2011|1.9k
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
|JAMA Oncology|2019|472
Post-hepatectomy haemorrhage: a definition and grading by the International Study Group of Liver Surgery (ISGLS)
|HPB|2011|451
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial
|The Lancet. Gastroenterology & hepatology|2022|255